Paloma Cejas
Head of Innovation/Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2026
Advanced prostate cancer remains a leading cause of cancer-related death among men due to disease progression in nearly all patients on standard-of-care therapy targeting the androgen receptor. An important mechanism driving therapeutic resistance is lineage plasticity, which enables prostate cancer cells to reprogram into lineage variants no longer dependent on androgen receptor signaling. As inhibitors of the histone methyltransferase enhancer of zeste homolog 2 (EZH2) are being evaluated clinically for the treatment of advanced prostate cancer, we investigated in this study how EZH2 affects prostate cancer lineage plasticity. Data from genetically engineered mice and human clinical samples demonstrated that genetic or pharmacologic suppression of EZH2 altered chromatin to expand active transcription factor programs. These changes in gene expression during prostate cancer progression increased the diversity of prostate cancer lineage variants that arose. EZH2 suppression did not inhibit disease progression nor therapeutic resistance in this context. These findings advance the current understanding of prostate cancer lineage plasticity and suggest that EZH2 inhibitors may be less effective in treating prostate cancer prone to lineage plasticity. Significance: EZH2 suppression diversifies prostate cancer lineage plasticity, which has implications for EZH2-targeted therapies that are being evaluated for prostate cancer treatment. See related commentary by Thienger et al., p. 827
Year:
2026
Residual disease remains a major obstacle for achieving durable responses in patients treated with oncogene-targeted therapy. Drug-tolerant persister (DTP) cells emerging under treatment and persisting in residual tumors are considered to be the root of acquired resistance, yet their contribution to immune evasion in on-treatment tumors is poorly defined. Here, we show in the context of EGFR-mutant lung cancer that DTP cells actively contribute to the formation of an immunosuppressive tumor microenvironment during EGFR tyrosine kinase inhibitor (TKI) therapy. In syngeneic mouse models and in patients, EGFR TKI therapy leads to an accumulation of immunosuppressive macrophages, which is strictly treatment-dependent and fully reversible upon treatment cessation or progressive disease, respectively. Quiescent DTP cells directly drive the recruitment and immunosuppressive reprogramming of monocytes and macrophages through a YAP-driven secretome, and the DTP-reprogrammed monocytes suppress T cell proliferation and effector functions in vitro . Co-targeting YAP with a TEAD inhibitor ORM-47286 rewires the DTP secretome and inhibits macrophage reprogramming in vitro , and prevents immunosuppressive macrophage accumulation and improves the efficacy of EGFR TKI therapy in immunocompetent mouse models. Our findings highlight the previously unappreciated role of DTP cells in modulating the tumor microenvironment in on-treatment tumors, and position the treatment-induced YAP/TEAD activity in DTP cells as an important driver of adaptive immunosuppression during EGFR-targeted therapy.
Year:
2026
Year:
2025
Year:
2025
Inactivation of the VHL gene stabilizes HIF2α, which drives clear-cell renal cell carcinoma (ccRCC). The HIF2α inhibitor belzutifan is approved for ccRCC treatment, but de novo and acquired resistance are common. HIF2α, bound to ARNT, transcriptionally activates many genes. We performed CRISPR-mediated gene activation screens in HIF2α-dependent ccRCC lines treated with a belzutifan analog to identify HIF2α-responsive genes that confer cell-autonomous belzutifan resistance when not downregulated. Sustaining the expression of the HIF2α target gene CCND1 , encoding cyclin D1, promoted HIF2α independence/belzutifan resistance. This activity requires CDK4/6 activation by cyclin D1 but is not solely due to phosphorylation of the canonical cyclin D1 target, pRB. Indeed, ccRCC lines lacking all three pRB family members remained at least partially HIF2α-dependent. In this context, however, a kinase-defective cyclin D1 variant partially overrode belzutifan’s antiproliferative effects, suggesting that ccRCC promotion by cyclin D1 requires the phosphorylation of pRB paralogs and one or more kinase-independent cyclin D1 activities. Significance: We discovered that cyclin D1 is the key target of HIF2 driving the cell-autonomous proliferation of VHL -mutant kidney cancers and that cyclin D1 has targets beyond pRB in this setting. These findings have implications for treating kidney cancer with HIF2 inhibitors, alone or in combination with CDK4/6 inhibitors.
Year:
2025
High-Grade T1 (HGT1) Non-Muscle Invasive is an early-stage of Bladder Cancer (NMIBC) with an unpredictable relapse and recurrence rate. New biomarkers are needed for patient risk prediction and to determine treatment. Here, we analyze the molecular characteristics of HGT1 NMIBC by combining multi-omics at bulk and single-cell resolution. We have identified two chromatin states that reflect variable degrees of basal and luminal inflammatory characteristics. These subtypes show relevant functional differences and are associated with clinical outcome. Luminal-like inflammatory (LLI) tumors are associated with a significantly higher risk of progression. At a single-cell resolution, RNA-seq shows the existence of a high degree of intra-tumor heterogeneity with co-existence of LLI and Basal-like (BL) subtypes within the same tumor specimen. The immunohistochemical validation in an independent patient cohort reveals subtypes coexistence in more than 40% patients. The subtypes show distinct spatial features within the tissue with the BL subtype consistently being in close proximity to the vascular stroma and the LLI subtype towards the interior of the tumor mass. Spatial transcriptomics at a single cell resolution further validate the specific location of the subtypes. Altogether, our results illustrate the high intratumor heterogeneity existing in HGT1 NMIBC bladder cancer, with spatial features that suggest microenvironment crosstalk. Based on our findings, multitarget therapy could be needed to target the extensive intra-tumor heterogeneity existing in bladder cancer.
Year:
2024
Collaborators (21)
Heidi Haikala
Professor
University of Helsinki
Micah Tratt
Fred Hutch Cancer Center
Mark Long
Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center
Prashant K Singh
Director, Genomics Shared Resource
Roswell Park Comprehensive Cancer Center Department of Cancer Genetics
William Kaelin
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute
Toni Choueiri
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Jianmin Wang
Associate Professor
Roswell Park Comprehensive Cancer Center
Milos Gojkovic
University of Helsinki
Sonia Kung
-
William Sellers
Professor of Medicine
Dana-Farber Cancer Institute
Maija Hollmén
Principal Investigator
University of Turku
Chien-Kuang Ding
Assistant Professor
University of California, San Francisco
WENYU YU
Harvard University
Lynn Heasley
Professor and Chair
University of Colorado Anschutz Medical Campus
Karen Adelman
Professor
Harvard Medical School
David Goodrich
Distinguished Professor of Oncology
Roswell Park Comprehensive Cancer Center
Myles Brown
Emil Frei III Professor of Medicine
Dana-Farber Cancer Institute
Bruce Montgomery
University of Washington
Shariq Madha
Dana-Farber Cancer Institute
Tamer Onder
Professor
Koç University
Steffen Boettcher
Assistant professor
University Hospital of Zurich
Make your next move.
Prepare your application
Review drafts before you send them.